We investigated whether a young human leukocyte antigen (HLA)-matched unrelated donor (MUD) should be preferred as donor to an HLA-identical sibling (MRD) for older patients with myelodysplastic syndrome (MDS) (X50 years) who underwent allogeneic stem cell transplantation (AHSCT). Outcomes of 719 MDS patients with a median age of 58 years (range, 50-73 years) who received AHSCT from related (n ¼ 555) or unrelated (n ¼ 164) donors between 1999 and 2008 and reported to the European Group for Blood and Marrow Transplantation were analyzed. The median donor age of the MRD was 56 years (range: 35-78), in contrast to 34 years (range: 19-64) for the MUDs. Influence of donor's age on survival was not observed for MRD (hazard ratio (HR): 1.01 (95% confidence interval (CI): 0.99-1.02), P ¼ 0.2), but there was a significant impact of MUD's age on outcome (HR: 1.03 (95% CI: 1.01-1.06); P ¼ 0.02). Transplantation from younger MUDs (o30 years) had a significant improved 5-year overall survival in comparison with MRD and older MUDs (430 years): 40% vs 33% vs 24% (P ¼ 0.04). In a multivariate analysis, AHSCT from young MUD (o30 years) remained a significant factor for improved survival in comparison with MRD (HR: 0.65 (95% CI: 0.45-0.95), P ¼ 0.03), which should be considered in donor selection for older patients.
INTRODUCTION
Allogeneic stem cell transplantation (AHSCT) for patients with myelodysplastic syndrome (MDS) is a curative treatment approach. [1] [2] [3] [4] Recent improvement in supportive care and the introduction of dose-and toxicity-reduced regimens allows now to perform AHSCT from related as well as from unrelated donors also in elderly patients with MDS. [5] [6] [7] Owing to improvement of life expectancy in general and reduction of risk from transplant, many elderly patients with MDS are now asked to be considered for an AHSCT with curative intention. In general, if a patient is considered a candidate for AHSCT, donor search is first performed within the siblings of the patient. Only if no human leukocyte antigen (HLA)-identical sibling is available, an unrelated donor search will be started. Although for unrelated donors, donor age is (beside HLA mismatch) a major factor for outcome after transplantation, 8, 9 this effect cannot be observed after HLA-identical-sibling transplantation as effect of donor age is masked by that of recipient's age, because sibling donors tend to have similar age as sibling recipients. In studies of related donor other than a HLAidentical sibling, also here an effect of donor age on outcome could be observed. 10 This study was performed addressing the question whether a young HLA-matched unrelated donor (MUD) should be preferred as donor to an HLA-identical sibling in elderly patients with MDS (X50 years of age) for AHSCT, who were reported to the European Group for Blood and Marrow Transplantation (EBMT).
PATIENTS AND METHODS
We selected from the EBMT (European Group for Blood and Marrow Transplantation) registry for patients with advanced MDS (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, secondary acute myelogenous leukemia and chronic myelomonocytic leukemia) and age 450 years. Furthermore, donor should be HLA-identical sibling or matched-unrelated stem cell donor. We identified 719 patients who fulfilled the criteria, and to have comparable groups in size we selected only patients who were transplanted between 1999 and 2008, and were reported to the EBMT; 555 of them received a graft from HLA-identical siblings, 164 of the patients from MUDs. The patients' characteristics are listed in Table 1 .
Statistical methods
Endpoints were overall survival (OS) and relapse-free survival (RFS). We also investigated non-relapse mortality, incidence of relapse and incidence of acute graft-versus-host disease (GvHD). Differences in the distributions of the risk factors in different age groups were compared using the w 2 statistic for categorical variables, and the Kruskal-Wallis test for continuous variables. Univariate cumulative survival probabilities were estimated by the Kaplan-Meier method and the log-rank test was used to compare survival curves. In order to account for competing events non-relapse mortality was considered a competing event for relapse. The OS and RFS were reported for 5 years.
In a first step, the following factors were univariately analyzed by logrank test: patient's age at transplantation, patients' sex, sex mismatch vs match, donor type, donor age, time from diagnosis to stem cell transplantation, stem cell source (bone marrow vs peripheral blood stem cells), standard vs reduced-intensity conditioning, year of stem cell transplantation, cytogenetic, disease status at diagnosis and remission status at transplantation.
In a second step, all pre-transplant factors with a P-value o0.1 in the univariate analysis were entered in a multivariate Cox regression model (backward elimination) to identify the most significant independent prognostic factors affecting OS after transplantation. The proportionality assumption was checked with the Harrell and Lee proportional hazards test. The estimated hazard ratios (HRs) together with the 95% confidence intervals (CIs) are reported for the final models. Calculations were performed with SPSS, version 15 (SPSS Inc., Chicago, IL, USA). For the donor age and donor type interaction we used following model:
That is donor_age as a continuous variable in the main and in the interaction term. As mentioned above, we used a backward elimination procedure and got a significant interaction effect (P ¼ 0.036) and the donor_type was eliminated from the model with no effect (P ¼ 0.462). For the multivariable setting including all potential confounders, we preferred the new defined variable-combining age and type-by categorizing the donors in related donors, unrelated age o30 years and unrelated age X30 years for reason of better interpretation of the results. Overall survival Figure 1 . OS according to age of related and unrelated donors in elderly MDS patients (450 years) who underwent AHSCT (adjusted rates are for disease status, stem cell source, cytogenetic and patient's age).
RESULTS
, but there was a significant impact of MUD's age on outcome (HR: 1.03 (95% CI: 1.01-1.06); P ¼ 0.02( (see Figure 1 ). In a next step, we defined the following three groups: (1) HLA-identical sibling, (2) MUD donor o30 years of age and (3) MUD donor X30 years of age. The characteristics of these three groups are shown in Table 2 . The group of the HLA-identical sibling was not divided as there was no difference in OS if the donor was o or 450 years of age.The estimated 5 year RFS and OS probabilities in percentage for these three groups are shown in Table 3 . Compared with HLA-identical siblings the 5 year OS of younger MUD (o30 years) was higher (40% vs 33%) and lower in older MUD (430 years; 24% vs 33%; Figure 1 ).
Further on in the univariate analysis, we found the following differences for the 5 year RFS and OS-see Table 3 : secondary acute myelogenous leukemia vs refractory anemia with excess blasts/ refractory anemia with excess blasts in transformation : 23% vs 31% (P ¼ 0.001) and 26% vs 35% (P ¼ 0.001); normal vs abnormal cytogenetics: 38% vs 24% (Po0.001) and 42% vs 26% (Po0.001); standard vs reduced-intensity conditioning: 25% vs 31% (P ¼ 0.07) and 27% vs 36% (P ¼ 0.01); peripheral blood stem cells vs BM: 31% vs 20% (P ¼ 0.002) and 35% vs 24% (P ¼ 0.008) and remission status at time of transplantation: complete remission (CR) vs non-CR: 38% vs 23%, (Po0.001) and 44% vs 25% (Po0.001). The year of transplantation as continuous variable did influence OS (HR: 0.963 Abbreviations: ASCT, allogeneic stem cell transplantation; CMML, chronic myelomonocytic leukemia; CMV, cytomegalovirus; CR, complete remission; HLA, human leukocyte antigen; IgG, immunoglobulin G; MUD, matched unrelated donor; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; sAML, secondary acute myelogenous leukemia; SCT, stem cell transplant. Non-relapse mortality, relapse and GvHD There was a trend for lower risk of relapse (3 years) and lower nonrelapse (at 1 year) mortality for patients transplanted from younger HLA-MUDs in comparison with HLA-identical sibling transplantation (32% vs 38% (P ¼ 0.26) and 16% vs 27%; (P ¼ 0.26), respectively; see Figure 2 . The incidence of acute GvHD did not differ between both groups (grade II-IV: 30% vs 25%, P ¼ 0.52). .001) remained significant factors, whereas disease status at transplantation and intensity of the conditioning regimen were not anymore significant in the multivariate analysis. We analyzed separately the effect of donor age for related and unrelated donors on OS, there was no effect of donor age in the group of related but a clear effect in the group of unrelated donors. As the number of unrelated donors is quite smaller compared with the number of related donors, this age effect is masked in the combined model. Using an unadjusted model with donor type, donor age (continuous) and an interaction term donor age Â donor type we get a significant interaction term, indicating that the age effect on OS changed with increasing age of the unrelated donors. The chosen cutoff point was 30 years. Therefore, we constructed a new variable (donor type/donor age) and this variable was added and maintained in the multivariate analysis although it was not significant in the univariate analysis, because it might be a confounder especially for the matched related transplantation, but in our data it had no effect on OS and did not alter the estimated coefficients (see Table 4 ). Also young unrelated donors (o30 years) had improved survival in comparison with sibling transplantation (HR: 0.65 (95% CI: 0.45-0.95), P ¼ 0.03).
Multivariate analysis

DISCUSSION
AHSCT for elderly patients with advanced MDS has become a reasonable curative treatment option. However, the role of Abbreviations: CI, confidence interval; CMML, chronic myelomonocytic leukemia; CMV, cytomegalovirus; IgG, immunoglobulin G; OS, overall survival; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; RFS, relapse-free survival; sAML, secondary acute myelogenous leukemia.
Donor selection according to age in elderly MDS patients N Krö ger et al AHSCT in elderly MDS patients in comparison with conventional therapies such as 5-azacytidine is less defined and is being currently investigated in prospective trials. 11 The increasing number of unrelated volunteer donors has increased the likelihood to find a HLA-compatible donor. Although in general, donor search is performed within the patient's family, and if a HLA-identical sibling is found, he/she will usually serve as stem cell donor. In the literature for matched-unrelated stem cell transplantation, outcome is determined by HLA matching and donor's age. Kollman et al. 8 reported for the National Marrow Donor Program a 5-year survival for patients who received matched unrelated grafts from donors with 18 to 30 years of age of 33%, from donors with 31 to 45 years of age of 29% and from donors with 445 years of age of only 25%. A higher incidence of acute and chronic GvHD was reported with increasing age of the donor. In a Spanish trial of matched unrelated stem cell transplantation in chronic myeloid leukemia, HLA matching and donor's age were the only significant factors for survival in the multivariate analysis. 9 Here, we analyzed from a large EBMT database the effect of donor age from MUD and from HLA-identical sibling, if the patient belonged to an elderly patient cohort (450 years of age). Although there was no significant impact of donor's age in the sibling group, for MUD donor age significantly influenced outcome, and confirmed the reported effects of donor's age in MUD transplantation. 8, 9 By taking into account the strong interaction of donor age and donor type, we developed a model, which suggested that in elderly MDS patients (450 years of age) a match unrelated donor should be preferred as donor to a HLA-identical sibling if donor's age of UD is young. In contrast with increasing donor age of MUD the survival becomes worse in comparison with HLA-identical sibling. However, it should be taken into account that the number of young MUD in this study was rather low and the donor's age effect in elderly patients should be confirmed in a larger group of patients including also other diseases. As donor age and donor type are heavily correlated, these observational data serve only to generate hypotheses. In this trial, we found also the well-known risk factors for survival in the multivariate analysis such as cytogenetic, disease and remission status at transplantation. Interestingly, we could also find a beneficial effect if peripheral blood stem cells were used as stem cell source. The role of stem cell source remains controversial, but at least for MDS the EBMT has shown in a previous study improved outcome if peripheral blood stem cells were used in comparison with bone marrow, mainly due to lower risk of therapy-related death as well as reduced risk of relapse. 12 What could be the reason for the observed donor's age effect in unrelated stem cell transplantation? In our study, the effect of survival was mainly due to a nonsignificant trend for lower risk of relapse, as well as for treatment-related mortality for younger MUDs.
In the aforementioned National Marrow Donor Program study, age of the donor correlated with incidence of acute and chronic GvHD but in our trial no significant difference of GvHD could be observed within the different age categories of the unrelated donors. Probably owing to the close association of donor age and recipient's age in HLA-identical sibling transplantation, a donor age effect has not been observed in our and other studies from HLA-identical sibling transplantation. Abbreviations: CI, confidence interval; CMML, chronic myelomonocytic leukemia; CR, complete remission; HR, hazard ratio; OR, odds ratio; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; sAML, sAML, secondary acute myelogenous leukemia.
Donor selection according to age in elderly MDS patients N Krö ger et al
It has been hypothized that because of higher exposure to foreign antigen of elderly donors, the tolerance may decrease of time with less naïve T cells and more memory T cells. 13 Other investigators observed a correlation between young donor's age and less graft failure, 14 or less chronic GvHD of the lung in children. 15 In our trial, time from diagnosis to transplantation was significantly longer for the MUD than for the sibling transplantation. It might be possible that the transplant is delayed while searching for a suitable donor. During donor search patient may relapse or achieve more unfavorable risk factors. Even if disparities between donor age and recipient age especially in the unrelated donor setting cannot be excluded by statistical methods, only a prospective randomized comparison could prove the hypothesis that younger MUD should be preferred to older sibling as donor in elderly patients who undergo AHSCT. In such a trial, time to transplant as well as other factors such as gender, cytomegalovirus status, donor/recipient gender combination should be taken into account and well balanced between the groups. If our results will be confirmed, this will have a major impact on donor selection in elderly patients, starting additional immediate unrelated donor search, irrespectively of available HLA-identical siblings. Furthermore, the donor registries and health authorities should encourage young volunteers to become stem cell donor.
